Our study further found that YVAD, a caspase-1 inhibitor, could effectively alleviate bleomycin-induced pulmonary fibrosis both by downregulating the NLRP3 inflammasome and reducing the activity of EndoMT. This evidence concerns the gene NLRP3 and pulmonary fibrosis.